Strategies for Anticoagulation During Venovenous ECMO

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Acute Hypoxemic Respiratory FailureAnticoagulant-induced BleedingThromboembolism
Interventions
OTHER

Low intensity anticoagulation

Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.

OTHER

Moderate Intensity Anticoagulation

"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."

Trial Locations (1)

37209

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER